Table 1. Clinical characteristics of premenopausal patients.
|
Singapore (n=164) |
Lebanon (n=78) |
POSH (n=345) |
Overall (n=587) |
P-valuea | |||||
|---|---|---|---|---|---|---|---|---|---|
| No. of patients | % | No. of patients | % | No. of patients | % | No. of patients | % | ||
| Follow-up, years | <0.001 | ||||||||
| Median | 4.0 | 4.1 | 6.4 | 5.5 | |||||
| Range | 1.3–14.2 | 1.9–8.5 | 1.2–11.6 | 1.2–14.2 | |||||
| Age at diagnosis, years | <0.001 | ||||||||
| Median | 47.0 | 43.0 | 37.5 | 39.1 | |||||
| Range | 30.0–59.0 | 24.0–51.0 | 22.0–41.0 | 22.0–59.0 | |||||
| BMI | <0.001 | ||||||||
| ⩽30 | 153 | 93.3 | 62 | 79.5 | 272 | 78.8 | 487 | 82.9 | |
| >30 | 10 | 6.1 | 16 | 20.5 | 65 | 18.8 | 91 | 15.5 | |
| Unknown | 1 | 0.6 | 8 | 2.3 | 9 | 1.5 | |||
| Ethnicity | <0.001 | ||||||||
| Caucasian | 320 | 92.8 | 320 | 54.5 | |||||
| Asian | 164 | 100 | 5 | 1.4 | 169 | 28.8 | |||
| African | 15 | 4.3 | 15 | 2.6 | |||||
| Middle Eastern | 78 | 100 | 78 | 13.3 | |||||
| Unknown | 5 | 1.4 | 5 | 0.9 | |||||
| Tumor size (cm) | 0.004 | ||||||||
| ⩽2 | 95 | 57.9 | 30 | 38.5 | 174 | 50.4 | 299 | 50.9 | |
| 2–5 | 58 | 35.4 | 35 | 44.9 | 142 | 41.2 | 235 | 40.0 | |
| >5 | 11 | 6.7 | 13 | 16.7 | 20 | 5.8 | 44 | 7.5 | |
| Unknown | 9 | 2.6 | 9 | 1.5 | |||||
| Nodal status | 0.08 | ||||||||
| Negative | 92 | 56.1 | 40 | 51.3 | 159 | 46.1 | 291 | 49.6 | |
| Positive | 69 | 42.1 | 38 | 48.7 | 184 | 53.3 | 291 | 49.6 | |
| Unknown | 3 | 1.8 | 2 | 0.6 | 5 | 0.9 | |||
| Grading | 0.21 | ||||||||
| G1 | 14 | 17.9 | 38 | 11.0 | 52 | 8.9 | |||
| G2 | 35 | 44.9 | 178 | 51.6 | 213 | 36.3 | |||
| G3 | 27 | 34.6 | 125 | 36.2 | 152 | 25.9 | |||
| Unknown | 164 | 100 | 2 | 2.6 | 4 | 1.2 | 170 | 29.0 | |
| Hormone receptor status | 0.472 | ||||||||
| (ER or PR) Positive | 164 | 100 | 78 | 100 | 340 | 98.6 | 582 | 99.1 | |
| (ER and PR) Negative | 3 | 0.9 | 3 | 0.5 | |||||
| Unknown | 2 | 0.6 | 2 | 0.3 | |||||
| HER2 status | 0.252 | ||||||||
| Positive | 43 | 26.2 | 18 | 23.1 | 66 | 19.1 | 127 | 21.6 | |
| Negative | 112 | 68.3 | 60 | 76.9 | 158 | 45.8 | 330 | 56.2 | |
| Unknown | 9 | 5.5 | 121 | 35.1 | 130 | 22.1 | |||
| Chemotherapy | 0.001 | ||||||||
| Yes | 143 | 87.2 | 69 | 88.5 | 261 | 75.7 | 473 | 80.6 | |
| No | 21 | 12.8 | 9 | 11.5 | 84 | 24.3 | 114 | 19.4 | |
| CYP2D6 phenotypes | <0.001 | ||||||||
| PM/PM | 4 | 5.1 | 30 | 8.7 | 34 | 5.8 | |||
| hetEM/IM | 129 | 78.7 | 37 | 47.4 | 205 | 59.4 | 371 | 63.2 | |
| EM/UM | 33 | 20.1 | 37 | 47.4 | 110 | 31.9 | 180 | 30.7 | |
| Unknown | 2 | 1.2 | 2 | 0.3 | |||||
Abbreviations: BMI, body mass index; EM, extensive metabolizer; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; het, heterozygous; PM, poor metabolizer; POSH, Prospective study of Outcomes in Sporadic versus Hereditary breast cancer; PR, progesterone receptor; IM, intermediate metabolizer; UM, ultra rapid metabolizer.
a
Refers to test for differences between the three cohorts.